-
Piper Jaffray Raises PT On Simcere Pharmaceutical Group To $10
Tuesday, March 15, 2011 - 6:39amPiper Jaffray has raised the price target on Simcere Pharmaceutical Group (NYSE: SCR) from $8.40 to $10 and maintains its Neutral rating.
Read More >> -
Oppenheimer Reports On Strong 4Q For Simcere Pharmaceutical Group
Wednesday, March 9, 2011 - 10:08amIn a report published Oppenheimer, Simcere Pharmaceutical Group (NYSE: SCR) saw a strong 4Q, and growing domestic market and sales investment could lead to upside. Oppenheimer said that SCR's 4Q was strong, with EPS of $0.16 significantly exceeding Street's consensus of $0.09, driven by a handsome...
Read More >> -
Simcere Pharmaceutical Group Reports Strong 3Q Results
Monday, November 15, 2010 - 10:33amOppenheimer's Quarterly Update on Simcere Pharmaceutical Group (NYSE: SCR) shows strong 3Q results. SCR had revenue of RMB542M which was higher than Oppenheimer's estimate of RMB491.8M and the Street's RMB536.9M. Gross margin was 84.8%, 1.1% higher than Oppenheimer's estimate. Oppenheimer writes...
Read More >> -
Simcere Pharmaceutical Group (SCR) Shares Down 2% On Earnings News
Tuesday, March 16, 2010 - 6:22pm
Shares of Simcere Pharmaceutical Group (NYSE: SCR) fell 2.14% on Tuesday, after rising costs led to the company missing Wall Street's profit estimates. Simcere Pharmaceutical Group reported that its 4th quarter profit fell 66% to $2.6 million, or 5 cents per share, on revenue of $79 million, which...
Read More >>
